Half-Year 2022 Financial and Clinical Trials Update
Pharma Division sales HY 2022
Top 20 products
Roche
Global
US
Europe
Japan
International
CHFM
% CER
CHFM
% CER
CHFM
% CER
CHFM
% CER
CHFM % CER
Ocrevus
2,910
17
2,140
11
539
34
231
43
Perjeta
2,061
5
740
1
457
-17
120
-1
744
34
Hemlibra
1,826
30
1,098
26
360
30
180
19
188
89
Tecentriq
1,758
11
951
13
383
19
218
-7
206
9
Actemra/RoActemra
1,455
-10
664
-7
420
-3
174
4
197
-37
Herceptin
1,179
-16
263
-27
233
-11
28
-28
655
-11
Avastin
1,142
-29
342
-38
116
-53
263
-13
421
-20
MabThera
1,117
-21
691
-22
Kadcyla
1,074
14
415
-1
Xolair
1,025
11
1,025
11
Alecensa
745
19
207
19
Ronapreve
609
11
༄ཤྩ'¥8
105
-17
17
-8
304
-19
350
10
68
23
23
241
52
-
149
7
114
6
275
65
-86
467
7275
37
-30
Lucentis
572
-17
572
-17
TNKase/Activase
559
-10
531
-10
Evrysdi
500
106
227
32
152
489
38
Esbriet
457
-14
313
-17
127
-2
Gazyva
349
8
161
2
95
-6
28
20
-2
G187
28
1
83
65
-36
65
88
Phesgo
325
241
138
155
163
338
24
403
Pulmozyme
279
0
184
2
51
-11
44
4
CellCept
270
-8
20
-16
68
-7
29
-8
153
-6
Pharma Division
22,347
3
11,363
1
4,104
-4
2,202
34
4,678
2
CER = Constant Exchange Rates (avg. full year 2021)
165View entire presentation